Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Asset Writedowns and Impairment: 2010-2024

Historic Asset Writedowns and Impairment for China Pharma Holdings (CPHI) over the last 13 years, with Dec 2024 value amounting to $450,738.

  • China Pharma Holdings' Asset Writedowns and Impairment rose 1627.90% to $25,302 in Q3 2025 from the same period last year, while for Sep 2025 it was $227,467, marking a year-over-year increase of 60.73%. This contributed to the annual value of $450,738 for FY2024, which is 2960.56% up from last year.
  • As of FY2024, China Pharma Holdings' Asset Writedowns and Impairment stood at $450,738, which was up 2,960.56% from -$15,757 recorded in FY2023.
  • China Pharma Holdings' Asset Writedowns and Impairment's 5-year high stood at $450,738 during FY2024, with a 5-year trough of -$255,215 in FY2021.
  • Over the past 3 years, China Pharma Holdings' median Asset Writedowns and Impairment value was -$15,757 (recorded in 2023), while the average stood at $113,710.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 321.57% in 2021, then soared by 2,960.56% in 2024.
  • China Pharma Holdings' Asset Writedowns and Impairment (Yearly) stood at $115,186 in 2020, then slumped by 321.57% to -$255,215 in 2021, then skyrocketed by 63.23% to -$93,851 in 2022, then soared by 83.21% to -$15,757 in 2023, then spiked by 2,960.56% to $450,738 in 2024.